Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2010

View Archived Issues

SYN-115 enhances effects of levodopa in Parkinson's disease patients

FDA approves labeling update for Tibotec's Prezista for HIV-1

IND to test androxal in men with type 2 diabetes and hypogonadism now effective

Gilead reports fourth quarter 2009 results

PROSPER data indicate no effect of pravastatin sodium on cognitive decline in the elderly

Antitumor activity of GMX-1777 plus radiotherapy seen in head and neck cancer models

Possible correlation between gender and genotype reported in pediatric onset of CD

AstraZeneca discloses novel Nav1.7 voltage-gated sodium channel blockers

Princeton University claims quorum-sensing signaling modulators for bacterial infections

Boehringer Ingelheim claims new chemokine CCR10 receptor antagonists

Labopharm receives FDA approval for Oleptro for major depressive disorder

Pharmasset describes new prodrugs of NS5B inhibitors

New antiepileptic agents described by University of North Carolina at Chapel Hill

FDA requests additional information for Protalix's taliglucerase alfa NDA

Onyx agrees with the FDA on a SPA for planned phase III carfilzomib trial

Vantia's VA-106483 enters phase IIb trial for nocturia

FDA approves Xiaflex for debilitating hand disease

Recordati receives European approval for silodosin for BPH

NeuroSearch presents topline results from phase III Huntexil study

Evotec and Vifor sign agreement to identify preclinical candidate in anemia

Spectrum and TopoTarget sign agreement for HDAC inhibitor belinostat

FDA accepts for formal review Javelin's NDA for NSAID Dyloject

EMEA issues scientific advice to Hybrigenics for clinical development of inecalcitol

Seattle and Millennium initiate phase I combination clinical trial of brentuximab

Oxytocin attenuates methamphetamine self-administration in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...